Aeterna Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>AZ</div>
AEZS -- USA Stock  

USD 0.68  0.02  3.03%

Aeterna Zentaris Enterprise Value over EBIT is relatively stable at the moment as compared to the past year. Aeterna Zentaris reported last year Enterprise Value over EBIT of 4.60. As of 12/28/2020, Gross Margin is likely to grow to 0.24, while Earnings before Tax are likely to drop (6.7 M). While some baby boomers are getting worried about healthcare space, it is reasonable to sum up Aeterna Zentaris. I will take a closer look at this stock and the latest sentiment generated by retail investors. This post is to show some fundamental factors affecting Aeterna Zentaris' products and services. I will also report how it may impact the investing outlook for the company in January.
Published over three weeks ago
View all stories for Aeterna Zentaris | View All Stories
Aeterna Zentaris (NASDAQ:AEZS) continues to spike
About 4.0% of Aeterna Zentaris shares are held by institutions such as insurance companies. Insiders ownership of Aeterna Zentaris refers to the amount of Aeterna Zentaris equity owned by Aeterna officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Aeterna, including its current ownership diagnostics.

Watch out for price decline

Please consider monitoring Aeterna Zentaris on a daily basis if you are holding a position in it. Aeterna Zentaris is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Aeterna Zentaris stock to be traded above the $1 level to remain listed. If Aeterna Zentaris stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Aeterna Zentaris's Liquidity

Aeterna Zentaris financial leverage refers to using borrowed capital as a funding source to finance Aeterna Zentaris ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Aeterna Zentaris financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Aeterna Zentaris's total debt and its cash.

How Aeterna utilizes its cash?

To perform a cash flow analysis of Aeterna Zentaris, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Aeterna Zentaris is receiving and how much cash it distributes out in a given period. The Aeterna Zentaris cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Aeterna Zentaris Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Aeterna Zentaris reported last year Net Cash Flow from Operations of (12.33 Million)

A Deeper Perspective

Aeterna Zentaris holds a total of sixty-two million six hundred eighty thousand outstanding shares. Aeterna Zentaris shows 6.29 percent if its outstanding shares held by insiders and 6.29 percent owned by other corporate entities . Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 2019 2020 (projected)
Interest Expense1.36 M1.33 M
Gross Profit122 K125.21 K

Ownership Breakdown

Retail Investors
Retail Investors89.27

Our perspective of the latest Aeterna Zentaris spike

Aeterna Zentaris latest skewness advances over 1.81. As of the 28th of December, Aeterna Zentaris shows the Mean Deviation of 3.45, downside deviation of 4.2, and Risk Adjusted Performance of 0.0838. Aeterna Zentaris technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Aeterna Zentaris, which can be compared to its rivals. Please confirm Aeterna Zentaris variance and potential upside to decide if Aeterna Zentaris is priced correctly, providing market reflects its regular price of 0.43 per share. As Aeterna Zentaris is a penny stock we also strongly suggest to validate its total risk alpha numbers.

While some other entities under the biotechnology industry are still a bit expensive, Aeterna Zentaris may offer a potential longer-term growth to retail investors. The inconsistency in the assessment between current Aeterna valuation and our trade advice on Aeterna Zentaris is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Aeterna Zentaris.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Aeterna Zentaris. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to